Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024Open Access

742 Neoadjuvant chemotherapy plus interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (NIHIPEC) in the treatment of advanced ovarian cancer: a multicentric propensity score study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaria Teresa Climent MartiHospital General Universitari de CastellóASAnna SerraHospital General Universitari de CastellóMGMar Bort Gimeno

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Marti et al. (2024) studied this question.

synapsesocial.com/papers/68e76835b6db6435876ddd99https://doi.org/10.1136/ijgc-2024-esgo.704
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 11325 Impact of HIPEC introduction in cytoreduction for ovarian cancer of ovarian origin: a real-world population study2024
  2. 2Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center2026 · 1 citations
  3. 3A Meta-Analysis on the Long-Term Impact of Cytoreductive Surgery Plus HIPEC for Ovarian Cancer with Peritoneal Metastasis: Are We on the Right Path?2026 · 1 citations
  4. 4HIPEC application potential in the treatment of extensive carcinomatosis in ovarian cancer (retrospective study)2024
  5. 5Neoadjuvant Chemotherapy Following Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Retrospective Cohort Study2026